Key result
Six months of SSRI treatment in children and adolescents did not significantly affect serum glucose or lipids, though a trend toward elevated LDL and reduced HDL was noted (p=0.06).
Why the study?
Does 6-month SSRI treatment affect metabolic parameters in children and adolescents with depressive and/or anxiety disorders?
Cohort (n=22)
Does 6-month SSRI treatment affect metabolic parameters in children and adolescents with depressive and/or anxiety disorders?
A 6-month course of SSRI treatment in children and adolescents appears metabolically safe with no significant changes in glucose or lipid profiles, though a trend toward worsened LDL and HDL was noted.
Answers are grounded in this paper and cite their sources.
Supports short-term metabolic neutrality of SSRIs in youth; leaves open longer-term lipid effects for randomized confirmation.
OBJECTIVES: Treatment with selective serotonin reuptake inhibitors (SSRIs) is common and is considered safe and effective in the treatment of anxiety and depressive disorders in pediatric populations. SSRI administration, however, is associated with adverse metabolic effects. The aim of this preliminary study was to evaluate the possible influence of a 6-month SSRI treatment on metabolic parameters in children and adolescents with depressive and/or anxiety disorders. METHODS: Metabolic parameters (glucose, cholesterol, triglycerides, low-density lipoprotein [LDL], and high-density lipoprotein [HDL]) were monitored in 22 children and adolescents (16 boys and 6 girls, aged 8-18 years) at baseline and after 6 months of SSRI treatment for depression and/or anxiety. RESULTS: Six months of SSRI treatment did not affect serum glucose, cholesterol, or triglycerides significantly, but a tendency (p = 0.06) toward elevation in serum LDL accompanied by a parallel reduction in HDL levels was detected. CONCLUSION: It appears that the 6-month SSRI treatment is metabolically safe in children and adolescents and does not affect the glucose or lipid profile. Long-term large-scale studies in pediatric populations focusing on the possible impact of long-term SSRI treatment (>6 months) on metabolic parameters are warranted.
No takes yet. Share an insight, caveat, or question.
Schapir et al. (2018) conducted a cohort in depressive and/or anxiety disorders (n=22). selective serotonin reuptake inhibitors (SSRIs) vs. baseline was evaluated on Metabolic parameters (glucose, cholesterol, triglycerides, LDL, and HDL) (p=0.06). Six months of SSRI treatment in children and adolescents did not significantly affect serum glucose or lipids, though a trend toward elevated LDL and reduced HDL was noted (p=0.06).
Synapse has enriched 10 related papers. Consider them for comparative context: